The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

The second-largest insulin brand also comes from Novo Nordisk’s portfolio, Ryzodeg, with a MAT of Rs 593 crore, followed by Sanofi’s Lantus. Why is human insulin no longer a priority? In high-income ...